-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
Changing the paradigm: circulating tumor DNA as a liquid biopsy for clinical biomarker assessments
Timothy R Wilson & Mark R Lackner
Clinical Trail Methodology: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
The UK Dermatology Clinical Trials Network: how far have we come?
Carron Layfield, Adrian Yong, Kim Thomas and Hywel Williams
Research Update: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Anti-cancer potential of tumor-vascular disrupting agents: review of the latest clinical evidence
Bruce C Baguley
Review: Clinical Trail Outcomes: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Inclusion of patients with brain metastases in clinical trials
Lauren E Abrey
Editorial: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation
-
Combination therapy for renal cell carcinoma: review of the clinical evidence
David F McDermott, Keith T Flaherty
Review Article: Clinical Investigation